Ponsegromab

Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.^{[1][2][3][4][5]}

Ponsegromab

Monoclonal antibody
Type	?
Target	GDF-15
Clinical data
Other names	PF-06946860
Legal status
Legal status	Investigational
Identifiers
CAS Number	2368950-15-4
UNII	GXA6PF0254

In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.^[6]